Anti- DXD antibody, mAb
抗DXD 鼠單克隆抗體
編號(hào)：YKMP18022
貨期：現(xiàn)貨
規(guī)格：25ug/100ug/1mg
Background
Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a). Dxd is cytotoxic to human cancer cell lines of KPL-4, NCI-N87, SK-BR-3, and MDA-MB-468 with IC50s of 1.43 nM-4.07 nM, but the control IgG-ADC (Dxd is the payload) shows no inhibition on the four cell lines (with HER2 expression). DS-8201a (Dxd is the payload) displays significant suppression on the HER2-positive KPL-4, NCI-N87, and SK-BR-3 cell lines, with IC50 values of 26.8, 25.4, and 6.7 ng/mL, respectively, but with no such inhibition on MDA-MB-468 (IC50, >10,000 ng/mL).
相關(guān)產(chǎn)品：
Anti- DXD antibody,mAb- Biotin 標(biāo)記
抗DXD鼠單克隆抗體-生物素標(biāo)記
編號(hào)：YKMP18022B
貨期：現(xiàn)貨
規(guī)格：25ul/100ul/1ml（可詢(xún)價(jià)）
Anti- DXD antibody,mAb- HRP 標(biāo)記
抗DXD鼠單克隆抗體-HRP標(biāo)記
編號(hào)：YKMP18022H
貨期：現(xiàn)貨
規(guī)格：25ul/100ul/1ml（可詢(xún)價(jià)）
